Printer Friendly

THERAGENICS ADDS CHARLES KLIMKOWSKI TO BOARD OF DIRECTORS; COMPANY ALSO RETAINS ALEX. BROWN & SONS AS FINANCIAL ADVISOR

 ATLANTA, Jan. 6 /PRNewswire/ -- Theragenics Corp. (NASDAQ: THRX), an Atlanta-based cancer therapy company, announced today that, effective Jan. 5, it had appointed Charles R. Klimkowsky to its board of directors. The appointment raises the number of Theragenics board members from five to six.
 Mr. Klimkowski, 57, has more than twenty years experience in the investment and financial fields. He presently serves as a senior vice president and director of the Chicago Corporation, a $130 million investment services organization which he joined in 1980. From 1972 to 1980, he was a private consultant to hundreds of tax-exempt corporate and institutional clients, for which he developed investment policy programs, analyzed pension plan liabilities, developed asset allocation strategies, hired investment managers and reviewed investment performance.
 For the seven years up to 1972, Klimkowski was with Nuclear Chicago, a subsidiary of G.D. Searle. In this capacity he was first involved with uses of nuclear measurement and detection instrumentation in the clinical, life and physical sciences, and later became the national sales manager for the company's in-vitro instrumentation group.
 Mr. Klimkowski is a member of the Institute of Chartered Financial Analysts, the Financial Analysts Federation and former chairman of the Continuing Education Committee of the Investment Analysts Society of Chicago. He holds a Bachelor of Science in Electrical Engineering from Fairleigh Dickinson University,.
 Chief Executive Officer John V. Herndon said Mr. Klimkowski will assist Theragenics in formulating financial policy and initiating certain investment matters.
 In another development, the company announced the hiring of Alex. Brown & Sons Incorporated to provide investment banking advice and services. Mr. Herndon said this action is part of an effort to focus the company's resources more sharply on shareholder and investor relations.
 Theragenics manufactures and markets TheraSeed, a radioactive implant used predominantly in the treatment of prostate cancer, the second most common cancer in men.
 -0- 1/6/93
 /CONTACT: Bruce Smith, CFO of Theragenics Corp., 404-381-8338, or


Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics/
 (THRX)


CO: Theragenics Corp. ST: Georgia IN: HEA SU: PER

AH-TS -- NY046 -- 2313 01/06/93 15:36 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 1993
Words:345
Previous Article:MGI PROPERTIES REPORTS 1992 RESULTS
Next Article:GARY J. RATHBURN NAMED MAPCO COAL VICE PRESIDENT - MARKETING
Topics:


Related Articles
THERAGENICS ANNOUNCES EXECUTIVE APPOINTMENTS
JHM MORTGAGE SECURITIES L.P. HOLDS QUARTERLY BOARD MEETING
BROWN ADVISORY & TRUST NAMES CHARLES W. COLE, JR. AS VICE CHAIRMAN; APPOINTS NEW DIRECTORS
IMMUNEX SPECIAL COMMITTEE REJECTS AHP OFFER
Network Imaging Selects Investment Banker
West TeleServices Committee to Study Proposal
McCormick Declares $0.12 Quarterly Dividend and Elects Margaret Preston to Board of Directors.
Theragenics Corporation(R) Appoints Bruce Smith as Acting Chief Financial Officer.
Theragenics Corporation(R) Announces Re-election of Directors After Annual Meeting.
Cincinnati Financial Corporation Subsidiaries Announce Appointments and Promotions.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters